NASDAQ:CNTB

Connect Biopharma Holdings American Depositary Shares Stock Earnings Reports

etoro logo Buy CNTB
*Your capital is at risk
$2.49
+0.370 (+17.45%)
At Close: Nov 17, 2025

Connect Biopharma Holdings American Depositary Shares Earnings Calls

Jun 30, 2025
-$0.230 (-4.55%)
Release date Aug 13, 2025
EPS estimate -$0.220
EPS actual -$0.230
EPS Surprise -4.55%
Revenue estimate -
Revenue actual 6.7K
Dec 31, 2024
-$0.190 (29.63%)
Release date May 15, 2025
EPS estimate -$0.270
EPS actual -$0.190
EPS Surprise 29.63%
Revenue estimate -
Revenue actual 261.879K
Jun 30, 2024
$0.0190 (167.49%)
Release date Sep 05, 2024
EPS estimate -$0.0281
EPS actual $0.0190
EPS Surprise 167.49%
Revenue estimate 2.949M
Revenue actual 3.319M
Revenue Surprise 12.54%
Mar 31, 2024
$0.0095 (129.74%)
Release date Apr 16, 2024
EPS estimate -$0.0320
EPS actual $0.0095
EPS Surprise 129.74%
Revenue estimate 2.92M
Revenue actual 1.667M
Revenue Surprise -42.91%

Last 4 Quarters for Connect Biopharma Holdings American Depositary Shares

Below you can see how CNTB performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Mar 31, 2024 Beat
Release date Apr 16, 2024
Price on release $1.73
EPS estimate -$0.0320
EPS actual $0.0095
EPS surprise 129.74%
Date Price
Apr 10, 2024 $1.86
Apr 11, 2024 $1.92
Apr 12, 2024 $1.72
Apr 15, 2024 $1.67
Apr 16, 2024 $1.73
Apr 17, 2024 $1.55
Apr 18, 2024 $1.52
Apr 19, 2024 $1.54
Apr 22, 2024 $1.35
4 days before -6.99%
4 days after -21.97%
On release day -10.40%
Change in period -27.42%
Jun 30, 2024 Beat
Release date Sep 05, 2024
Price on release $1.19
EPS estimate -$0.0281
EPS actual $0.0190
EPS surprise 167.49%
Date Price
Aug 29, 2024 $1.28
Aug 30, 2024 $1.60
Sep 03, 2024 $1.29
Sep 04, 2024 $1.29
Sep 05, 2024 $1.19
Sep 06, 2024 $1.25
Sep 09, 2024 $1.26
Sep 10, 2024 $1.27
Sep 11, 2024 $1.26
4 days before -7.03%
4 days after 5.88%
On release day 5.04%
Change in period -1.56%
Dec 31, 2024 Beat
Release date May 15, 2025
Price on release $0.727
EPS estimate -$0.270
EPS actual -$0.190
EPS surprise 29.63%
Date Price
May 09, 2025 $0.81
May 12, 2025 $0.80
May 13, 2025 $0.761
May 14, 2025 $0.770
May 15, 2025 $0.727
May 16, 2025 $0.751
May 19, 2025 $0.785
May 20, 2025 $0.85
May 21, 2025 $0.82
4 days before -10.22%
4 days after 12.10%
On release day 3.30%
Change in period 0.642%
Jun 30, 2025 Missed
Release date Aug 13, 2025
Price on release $2.36
EPS estimate -$0.220
EPS actual -$0.230
EPS surprise -4.55%
Date Price
Aug 07, 2025 $2.07
Aug 08, 2025 $2.07
Aug 11, 2025 $2.05
Aug 12, 2025 $2.27
Aug 13, 2025 $2.36
Aug 14, 2025 $2.15
Aug 15, 2025 $2.05
Aug 18, 2025 $1.92
Aug 19, 2025 $1.81
4 days before 14.01%
4 days after -23.31%
On release day -8.90%
Change in period -12.56%

Connect Biopharma Holdings American Depositary Shares Earnings History

Earnings Calendar

FAQ

When is the earnings report for CNTB?
Connect Biopharma Holdings Limited American Depositary Shares (CNTB) has scheduled its earnings report for Mar 30, 2026 before the markets open.

What is the CNTB price-to-earnings (P/E) ratio?
CNTB P/E ratio as of Nov 17, 2025 (TTM) is -3.26.

What is the CNTB EPS forecast?
The forecasted EPS (Earnings Per Share) for Connect Biopharma Holdings Limited American Depositary Shares (CNTB) for the first fiscal quarter 2025 is -$0.290.

What are Connect Biopharma Holdings Limited American Depositary Shares's retained earnings?
On its balance sheet, Connect Biopharma Holdings Limited American Depositary Shares reported retained earnings of $6.70 thousand for the latest quarter ending Jun 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CONNECT BIOPHARMA HOLDINGS LIMITED AMERICAN DEPOSITARY SHARES
Connect Biopharma Holdings American Depositary Shares
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosin...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE